MicuRx Pharmaceuticals released its 2026 interim report, with total operating revenue of 89.53 million yuan, net profit attributable to the parent company of negative 37.566 million yuan, and net cash flow from operating activities of negative 26.3929 million yuan. The company's asset-liability ratio was 74.04%, gross margin was 86.60%, ROE was negative 23.05%, and diluted earnings per share was negative 0.06 yuan. The number of shareholders was 16,700, and the top ten shareholders held 42.27% of the total share capital.
Shanghai MicuRx Pharmaceutical Co. Ltd. AReports net loss of 37.566 million yuan in interim report
